Currently, there is no established or routinely recommended stem cell therapy for treating autism spectrum disorder (ASD) in UK clinical practice. Standard care as per UK guidelines focuses on psychosocial interventions, behavioral support, management of coexisting mental health conditions, and symptom-targeted pharmacological treatments rather than disease-modifying therapies like stem cell treatmentNICE CKS,NICE CKS,NICE CG170.
However, emerging research from recent biomedical literature indicates that mesenchymal stem/stromal cell (MSC)-based therapies and their derivatives, including MSC-derived exosomes, represent a promising experimental approach for ASD treatment. These therapies aim to modulate underlying pathophysiological mechanisms of ASD such as neuroinflammation, synaptic dysfunction, immune dysregulation, and compromised neurodevelopmental processes, which are not addressed by current symptom-focused interventions Xu et al. 2026 Sun et al. 2026.
MSC therapies have been investigated in both animal models and early-phase human clinical trials (Phase I/II), using sources such as umbilical cord tissue, bone marrow, and adipose tissue. Initial findings from preclinical studies show improvements in social behaviors, repetitive actions, cognition, and reduction of neuroinflammation Xu et al. 2026. Clinical trials have reported that MSC treatments appear safe and may lead to improved language skills, social communication, and behavioral outcomes in children with ASD, though these are preliminary and mostly from small, open-label studies lacking long-term data Sun et al. 2026 Liu et al. 2026.
The therapeutic mechanisms proposed include immunomodulation by shifting microglia and macrophages to anti-inflammatory phenotypes, secretion of neurotrophic factors (like BDNF and GDNF) that promote synaptic plasticity and neurogenesis, enhancement of cerebral angiogenesis, and restoration of gut-brain axis communication Xu et al. 2026 Sun et al. 2026. Exosome-based cell-free therapies derived from MSCs provide a potentially safer, scalable alternative with lower immunogenicity and the ability to cross the blood-brain barrier Sun et al. 2026.
Despite these promising developments, important challenges remain, including the need for standardized protocols, robust quality control, reproducible dosing strategies, long-term safety and efficacy demonstration, and large-scale randomized controlled trials before any stem cell therapy can be recommended clinically Xu et al. 2026 Sun et al. 2026. Ethical considerations for cell sources and the heterogeneity of ASD further complicate clinical translation.
In summary, while stem cell therapies are an active area of research and may in future offer a mechanism-based treatment for ASD, there is currently no established stem cell treatment method available within UK clinical guidelines or routine practice for ASDNICE CKS,NICE CKS,NICE CG170 Xu et al. 2026 Sun et al. 2026.
Key References
- NICE CKS: Autism in adults
- NICE CKS: Autism in children
- NICE CG170: Autism spectrum disorder in under 19s: support and management
- NICE CG128: Autism spectrum disorder in under 19s: recognition, referral and diagnosis
- (Nabetani et al., 2023): Cell Therapies for Autism Spectrum Disorder Based on New Pathophysiology: A Review.
- (Nie et al., 2025): Human pluripotent stem cell (hPSC)-derived models for autism spectrum disorder drug discovery.
- (Liu et al., 2026): Stem Cell Therapy and Models for Autism Spectrum Disorder: Insights and Research.
- (Xu et al., 2026): Mesenchymal stem/stromal cell-based therapies for autism spectrum disorder: emerging evidence and clinical prospects.
- (Sun et al., 2026): <p>Harnessing MSC‑derived exosomes to modulate the pathophysiology of ASD: Recent advances and therapeutic implications (Review)</p>.